Recombinant Human PLA2G1B (C-6His)

Description

EnkiLife provides the Recombinant Human PLA2G1B (C-6His) protein,aslo know as PLA2G1B;Phospholipase A2;Group IB phospholipase A2;PLA2;PLA2A;PPLA2, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Phospholipase A2 Group IB is produced by our Mammalian expression system and the target gene encoding Ala23-Ser148 is expressed with a 6His tag at the C-terminus.Accession:P04054. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:15.2 KDa. Background:Phospholipase A2(PLA2G1B) is a secreted protein which belongs to the phospholipase A2 family. It catalyzes the release of fatty acids from glycero-3-phosphocholines. It catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. This releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules. Sequences of pancreatic PLA2G1B enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Mice lacking in PLA2G1B are resistant to obesity and diabetes induced by feeding a diabetogenic high-fat/high-carbohydrate diet. Oral supplementation of a diabetogenic diet with the PLA2G1B inhibitor methyl indoxam effectively suppresses diet-induced obesity and diabetes. PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of obesity and diabetes.